An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PERFlexS
- Sponsors Janssen-Cilag
- 23 Oct 2017 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 10 Jun 2017 Biomarkers information updated
- 04 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.